Gingivitis - Pipeline Insight, 2024

This “Gingivitis - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Gingivitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Gingivitis Understanding

Gingivitis: Overview

Gingivitis is a form of gum disease that happens when plaque, a naturally-occurring sticky film containing bacteria, builds up on teeth and causes the inflammation of the surrounding gum tissue. Plaque produces toxins that irritate the gums. This can cause the gums to become inflamed, making them red or puffy, or causing them to bleed. This harmful plaque bacteria can even lead to issues beyond gingivitis like weakened tooth enamel. Even with regular brushing, it's important to make sure you’re taking care of your gum line, because a healthy mouth starts there

Gingivitis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gingivitis pipeline landscape is provided which includes the disease overview and Gingivitis treatment guidelines. The assessment part of the report embraces, in depth Gingivitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gingivitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Gingivitis R&D. The therapies under development are focused on novel approaches to treat/improve Gingivitis.

Gingivitis Emerging Drugs Chapters

This segment of the Gingivitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gingivitis Emerging Drugs

Mycobactovir: LTN Pharm Mycobactovir is a Chitin synthase inhibitors being developed by LTN Pharma. The drug is currently in phase 2 stage of clinical trial evaluation for the treatment of patients withgingivitis.

AMY 101: Amyndas Pharmaceuticals AMY 101 is a Complement C3 inhibitor being developed by Amyndas Pharmaceuticals. The drug is currently in phase 2 stage of clinical trial evaluation for the treatment of patients with gingivitis.

Gingivitis: Therapeutic Assessment

This segment of the report provides insights about the different Gingivitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Gingivitis

There are approx. 3+ key companies which are developing the therapies for Gingivitis. The companies which have their Gingivitis drug candidates in the most advanced stage, i.e. phase II include, Amyndas Pharmaceuticals.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Gingivitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Gingivitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gingivitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gingivitis drugs.

Gingivitis Report Insights

• Gingivitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Gingivitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Gingivitis drugs?
• How many Gingivitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gingivitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Gingivitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Gingivitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• LTM Pharm
• Amyndas Pharmaceuticals
• Aphios
• Biomedical Development Corporation
• Colgate Palmolive

Key Products

• Mycobactovir
• AMY 101

Research programme: marine anti-plaque compounds- Iodine-based oral rinse


This product will be delivered within 2 business days.